Edwards Lifesciences Corporation (NYSE:EW) Receives $100.27 Consensus PT from Brokerages

Shares of Edwards Lifesciences Corporation (NYSE:EW) have been given a consensus recommendation of “Moderate Buy” by the twenty-three analysts that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $100.2727.

EW has been the subject of several analyst reports. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $87.00 to $101.00 in a report on Friday, July 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Royal Bank Of Canada raised their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, UBS Group began coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price target for the company.

Insider Transactions at Edwards Lifesciences

In other news, VP Annette Brüls sold 2,644 shares of the stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 5,045 shares of company stock valued at $457,749. Corporate insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently made changes to their positions in EW. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences in the first quarter valued at approximately $25,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter worth $25,000. MV Capital Management Inc. bought a new position in shares of Edwards Lifesciences in the 4th quarter worth $26,000. RMG Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 1st quarter valued at $26,000. Finally, Pin Oak Investment Advisors Inc. acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at $26,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $90.00 on Tuesday. The stock has a 50 day moving average price of $89.70 and a 200 day moving average price of $85.64. Edwards Lifesciences has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The stock has a market capitalization of $51.82 billion, a PE ratio of 51.72, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter last year, the company posted $0.67 earnings per share. Edwards Lifesciences’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts predict that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.